ClinicalTrials.Veeva

Menu

The 10/7 HIIT Shock Cycle Study: Effectiveness of 10 HIIT Sessions in 7 Days (THESIS)

U

University of Salzburg

Status

Completed

Conditions

Performance
Athlete
Healthy

Treatments

Other: Exercise

Study type

Interventional

Funder types

Other

Identifiers

NCT05067426
NHaller

Details and patient eligibility

About

A randomized, controlled trial to evaluate the effects of two versions of 10 high intensity interval trainings (HIIT) within a 7-day shock microcycle on endurance performance, well-being, health, stress and recovery in trained athletes.

Full description

Thirty-six trained endurance athletes will be recruited and randomly assigned to either a "high volume (HIIT-HV)" group, a "low volume (HIIT-LV)" group, or a control group. All participants will be monitored before (9 days), during (7 days), and after (14 days) a 7-day training intervention, for 30 days. Participants in both intervention groups will complete 10 HIIT sessions within the period of 7 days, with an additional 30 minutes of low-intensity training exclusively in HIIT-HV. HIIT sessions consist of aerobic HIIT, i.e., 5x4min at 90-95% of maximal heart rate interspersed by 2.5 min active recovery periods. To determine the effects of the intervention, performance diagnostics, and a 5 kilometer time trial will be conducted before and after the intervention. In addition, participants are closely monitored for general health, stress, fatigue, recovery, neuromuscular performance, executive functions and sleep.

Enrollment

33 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Female or male
  • aged 18-45 years
  • Proof of physical fitness (e.g. sports medical examination required) for measurements with higher intensities (e.g. endurance tests, competition simulation)
  • Competition experience at the national or international level in an endurance sport
  • VO2max ≥50ml/kg/min for females; ≥55 ml/kg/min for males or a 5-kilometer (km) time trial performance of ≤ 20:00 min (female), or ≤ 18:30 min (male)

Exclusion criteria

  • Systemic disease or other known pathology in the organs: heart, lungs, kidney, stomach, spleen, liver, gall bladder, and intestines.
  • Evidence of pulmonary disease: forced expiratory volume in one second/forced expiratory volume < 70% with/without symptoms (cough, sputum) or other evidence of pulmonologic disease.
  • Diabetes II.
  • Neurological or psychological disease of any kind.
  • Currently undergoing medical or psycho-therapeutic treatment.
  • Health condition that does not allow regular participation in the training forms (e.g. acute illnesses such as fever or other flu-like infections within the last 7 days before the start of the study), orthopedic diseases, injuries to the muscular, bone, joint or tendon apparatus within the last three months.
  • Alcohol or drug abuse.
  • Already high training volume with high intensity training (more than 2 weekly training sessions of high-intensity training)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

33 participants in 3 patient groups

HIIT-HV
Experimental group
Description:
HIIT-HV - high intensity interval training high volume Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period. Each training session is followed by 30 minutes of low-intensity training (total of 300 minutes of additional low-intensity training during this period).
Treatment:
Other: Exercise
HIIT-LV
Experimental group
Description:
HIIT- LV - high intensity interval training low volume Participants complete a total of 10 HIIT sessions over a 7-day period consisting of 5 x 4-minute intervals at an intensity of 90-95% of their individual maximum heart rate (HRmax), interspersed with a 2.5-minute active recovery period.
Treatment:
Other: Exercise
Control group
No Intervention group
Description:
Participants continue with their regular training program.

Trial contacts and locations

1

Loading...

Central trial contact

Nils Haller, PhD; Julia Blumkaitis, M.Sc.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems